OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Indexing: DOAJ-Directory of Open Access Journals.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 6 days from acceptance to publication (median values for papers published in this journal in the first half of 2020, 1-2 days of FREE language polishing time is also included in this period). A first decision provided to authors of manuscripts submitted to this journal are approximately 3.3 weeks (median values) after submission.
Cerebrovascular Biomarkers in Alzheimer's Disease
Submission Deadline: April 15, 2021 (Open) Submit Now
Jacques De Reuck, MD, PhD
Professor, Université Lille 2, INSERM U1171 Degenerative & Vascular Cognitive Disorders, Lille, France
Research Interests: Dementia; cognitive impairment; Alzheimer's disease; ischemic stroke; neurodegenerative diseases; cerebrovascular diseases; vascular dementia
About This Topic
The significance of small cerebrovascular lesions is frequently overlooked in patients with Alzheimer’s disease. These lesions are most commonly due to cerebral amyloid angiopathy, which is mainly associated in the end-stages of the disease. Also Alzheimer’s disease can be mixed with arteriosclerotic small-vessel disease. The most common small cerebrovascular lesions are cortical micro-bleeds, cortical micro-infarcts, white matter changes, lacunar infarcts and superficial cortical siderosis. These lesions can be best detected with 7.0-tesla magnetic resonance imaging in vivo and on post-mortem examination, when the diagnosis of Alzheimer’s disease has to be confirmed for the family.
The final message is that in patients with suspected Alzheimer’s disease the vascular risk factors, such as arterial hypertension, hypercholesterolemia and diabetes, have to be treated as early as possible and smoking has to be avoided.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.